台灣臨床試驗主持人資料庫|TPIDB

2017-02-24 - 2018-12-31

Others

Completed

A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Condition/Disease

RHEUMATOID ARTHRITIS
Test Drug

PF-06650833

Participate Sites
4Sites

Terminated3Sites

張棋楨

Taipei Medical University Hospital

黃春明

China Medical University Hospital-Taipei

未分科

2018-12-06 - 2025-12-31

Phase II

Active

A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

Condition/Disease

Neuroendocrine Tumors
Test Drug

CVM-1118

Participate Sites
8Sites

Recruiting4Sites

Terminated3Sites

陳明晃

Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

2016-12-29 - 2023-09-28

Phase III

Completed

A Phase III Trial of Chidamide in Combination with Exemestane in Patients with Hormone Receptor-Positive Advanced Breast Cancer (ACE)

Condition/Disease

Hormone Receptor-Positive Advanced Breast Cancer
Test Drug

NA

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

劉良智

China Medical University Hospital-Taipei

未分科

2018-12-01 - 2024-05-16

Phase II

Completed

A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)

Condition/Disease

systemic lupus erythematosus (SLE)
Test Drug

VAY736 (ianalumab)、CFZ533 (iscalimab)

Participate Sites
4Sites

Recruiting3Sites

藍忠亮

China Medical University Hospital

藍忠亮

China Medical University Hospital-Taipei

未分科

2017-04-27 - 2018-12-31

Phase I

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers

Condition/Disease

Gastric Cancer/Esophageal Cancer/Gastro-esophageal Cancer
Test Drug

Oraxol + Ramucirumab

Participate Sites
7Sites

Terminated6Sites

趙毅

Taipei Veterans General Hospital

Division of Radiation Therapy

白禮源

China Medical University Hospital-Taipei

未分科

2017-08-24 - 2019-09-30

Phase III

A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)

Condition/Disease

Small-Cell Lung Cancer (SCLC)
Test Drug

Durvalumab; Tremelimumab

Participate Sites
11Sites

Terminated10Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

夏德椿

China Medical University Hospital-Taipei

未分科

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Condition/Disease

Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
Test Drug

ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁

Taipei Veterans General Hospital

Digestive System Department

彭成元

China Medical University Hospital-Taipei

未分科

2015-10-20 - 2017-05-30

Phase III

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

Condition/Disease

Chronic Hepatitis C Virus Genotype 2 Infection
Test Drug

ABT-493/ABT-530

Participate Sites
7Sites

Terminated4Sites

Study ended1Sites

彭成元

China Medical University Hospital

Digestive System Department

彭成元

China Medical University Hospital-Taipei

未分科

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

Condition/Disease

Advanced Nasopharyngeal Carcinoma
Test Drug

Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

謝清昀

China Medical University Hospital-Taipei

未分科

2017-03-01 - 2019-12-31

Phase III

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

Condition/Disease

Advanced or Metastatic Gastric Cancer
Test Drug

Apatinib

Participate Sites
10Sites

Terminated8Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

Search Result

List